The current status and future directions of myxoma virus, a master in immune evasion - PubMed
- ️Sat Jan 01 2011
Review
The current status and future directions of myxoma virus, a master in immune evasion
Bart Spiesschaert et al. Vet Res. 2011.
Abstract
Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.
Figures

MYXV worldwide distribution. The global distribution of MYXV during the period 01/07/2009-31/12/2009 (copied from [152).

The pathogenesis of nodular myxomatosis. At the site of inoculation (A) viral replication occurs first in the peripheral epidermal cells and then in cells deeper in the dermis (B). This initially induces only a mild primary inflammation and mainly attracts neutrophils at early times. Resident Major Histocompatibility Complex-2 (MHC-2) positive cells, such as Langerhans cells, are also infected (C) [2,12,13]. When these cells migrate to the draining lymph node to present viral epitopes in the T-cell zone, they also traffic live virus and T-lymphocytes become infected with MYXV as well (D). This results in wide spread cell death in the T-cell zone of many lymphoid organs and also enables MYXV to spread in a cell-associated manner when these infected T-lymphocytes migrate through the blood and reticuloendothelial circulation. Once in the blood and lymph, MYXV spreads via infected leukocytes to different organs such as the liver, spleen, other distant lymph nodes, testis and epidermis (E). The MYXV replication in these organs induces a strong polymorphonuclear (PMN) cell-influx and in the skin secondary lesions are formed that contain high viral titers, favoring successful spread by mechanical vectors (F) [2,12].
Similar articles
-
Boutard B, Vankerckhove S, Markine-Goriaynoff N, Sarlet M, Desmecht D, McFadden G, Vanderplasschen A, Gillet L. Boutard B, et al. PLoS One. 2015 Feb 23;10(2):e0118806. doi: 10.1371/journal.pone.0118806. eCollection 2015. PLoS One. 2015. PMID: 25705900 Free PMC article.
-
Kerr PJ, Rogers MB, Fitch A, Depasse JV, Cattadori IM, Hudson PJ, Tscharke DC, Holmes EC, Ghedin E. Kerr PJ, et al. J Virol. 2013 Nov;87(22):12080-9. doi: 10.1128/JVI.01923-13. Epub 2013 Aug 28. J Virol. 2013. PMID: 23986601 Free PMC article.
-
Genetic Variability of Myxoma Virus Genomes.
Braun C, Thürmer A, Daniel R, Schultz AK, Bulla I, Schirrmeier H, Mayer D, Neubert A, Czerny CP. Braun C, et al. J Virol. 2017 Jan 31;91(4):e01570-16. doi: 10.1128/JVI.01570-16. Print 2017 Feb 15. J Virol. 2017. PMID: 27903800 Free PMC article.
-
Kerr PJ, Best SM. Kerr PJ, et al. Rev Sci Tech. 1998 Apr;17(1):256-68. doi: 10.20506/rst.17.1.1081. Rev Sci Tech. 1998. PMID: 9638815 Review.
-
Immune responses to myxoma virus.
Kerr P, McFadden G. Kerr P, et al. Viral Immunol. 2002;15(2):229-46. doi: 10.1089/08828240260066198. Viral Immunol. 2002. PMID: 12081009 Review.
Cited by
-
Herbert MH, Squire CJ, Mercer AA. Herbert MH, et al. Viruses. 2015 Feb 16;7(2):709-38. doi: 10.3390/v7020709. Viruses. 2015. PMID: 25690795 Free PMC article. Review.
-
Yaron JR, Zhang L, Guo Q, Awo EA, Burgin M, Schutz LN, Zhang N, Kilbourne J, Daggett-Vondras J, Lowe KM, Lucas AR. Yaron JR, et al. Pharmaceutics. 2020 Oct 22;12(11):1003. doi: 10.3390/pharmaceutics12111003. Pharmaceutics. 2020. PMID: 33105865 Free PMC article.
-
Lemos de Matos A, McFadden G, Esteves PJ. Lemos de Matos A, et al. Immunogenetics. 2014 Jan;66(1):43-52. doi: 10.1007/s00251-013-0740-7. Epub 2013 Nov 13. Immunogenetics. 2014. PMID: 24220721
-
Oncolytic myxoma virus: the path to clinic.
Chan WM, Rahman MM, McFadden G. Chan WM, et al. Vaccine. 2013 Sep 6;31(39):4252-8. doi: 10.1016/j.vaccine.2013.05.056. Epub 2013 May 29. Vaccine. 2013. PMID: 23726825 Free PMC article. Review.
-
Emerging viruses and current strategies for vaccine intervention.
Afrough B, Dowall S, Hewson R. Afrough B, et al. Clin Exp Immunol. 2019 May;196(2):157-166. doi: 10.1111/cei.13295. Clin Exp Immunol. 2019. PMID: 30993690 Free PMC article. Review.
References
-
- Saari SA, Rudback E, Niskanen M, Syrjala P, Nylund M, Anttila M. Contagious mucocutaneous dermatitis of the mountain hare (Lepus timidus): pathology and cause. J Wildl Dis. 2005;41:775–782. - PubMed
-
- Fenner F, Ratcliffe F. Myxomatosis. University Press, Cambridge Eng; 1965.
-
- Fenner F. Deliberate introduction of the European rabbit, Oryctolagus cuniculus, into Australia. Rev Sci Tech. 2010;29:103–111. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources